Investigation Alert: Levi & Korsinsky Investigates Securities Fraud Claims Against aTyr Pharma, Inc. (ATYR)

New York, New York--(Newsfile Corp. - September 19, 2025) - Levi & Korsinsky notifies investors that it has commenced an investigation of aTyr Pharma, Inc. ("aTyr Pharma, Inc.") (NASDAQ: ATYR) concerning possible violations of federal securities laws.

On September 15, 2025, aTyr published a press release announcing topline results from the Company's Phase 3 EFZO-FIT study of efzofitimod, stating that the trial failed to meet its primary endpoint. The study was conducted in 268 patients with pulmonary sarcoidosis, a major form of interstitial lung disease. Following this news, aTyr hit a new 52-week low following several analyst downgrades.

Following this news, aTyr's stock price fell over 83.3% to close at $1.01 per share on September 15, 2025. To obtain additional information, go to:

https://zlk.com/pslra-1/atyr-pharma-inc-lawsuit-submission-form?prid=168400&wire=5&utm_campaign=57

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212)363-7500.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/267131